GlaxoSmithKline Pharmaceuticals Limited announced its decision to transfer its rights in relation to the Iodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited, subject to shareholder approval, for an aggregate consideration of Rs 1649 crores. The company also declared its financial results for the quarter ended June 30, 2021. Revenue for the quarter came in…